STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-225)	TUSAMITAMAB RAVTANSINE
PRONUNCIATION	too” sa mit’ a mab rav tan’ seen
THERAPEUTIC CLAIM	Antineoplastic

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human carcinoembryonic antigen-related cell adhesion molecule 5) (human monoclonal SAR408377 γ1-chain), disulfide with human monoclonal SAR408377 κ-chain, dimer, amide with N2'-[4-[(3-carboxypropyl)dithio]-4-methyl-1-oxopentyl]-N2'-deacetylmaytansine (Source: CAS)

2. immunoglobulin G1-kappa, anti-[*Homo sapiens* Carcinoembryonic antigen-related cell adhesion molecule 5 (Carcinoembryonic antigen, Meconium antigen 100, antigen_CD66e)] humanized mouse monoclonal antibody; γ1 heavy chain (1-449) [VH(*Mus musculus* IGHV5-12-1*01 (87%) –(IGHD) -IGHJ3*01 (93%)/*Homo sapiens* IGHV3-23*01 (77%) IGHJ4*01 (93%)] [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 {CH3[K^{107}>del(450)]} (121-449) (223-214')-disulfide with κ light chain (1'-214') [V-KAPPA (*Mus musculus* IGKV12-44*01 (87%)-IGKJ4*01/*Homo sapiens* IGKV1-39*01 (82%) -IGKJ2*02 (91%)][6.3.9] (1'-107') *Homo sapiens* IGKC*01 (108'-214')], dimer (229-229'':232-232'')-bisdisulfide, produced in CHO cell, glycoform alfa; 3 or 4 (n) lysines are N^6 substituted by ravtansine

STRUCTURAL FORMULA

Heavy chains (X & X'')

EVQLQESGPG	LVKPGGSLSL	SCAASGFVFS	SYDMSWVRQT	PERGLEWVAY	50
ISSGGGITYA	PSTVKGRFTV	SRDNAKNTLY	LQMNSLTSED	TAVYYCAAHY	100
FGSSGPFAYW	GQGTLVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK	150
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT	200
YICNVNHKPS	NTKVDKKVEP	KSCDKTHTCP	PCPAPELLGG	PSVFLFPPKP	250
KDTLMISRTP	EVTCVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	350
VYTLPPSRDE	LTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTPPV	400
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPG	449

Light chains (X' & X''')

DIQMTQSPAS	LSASVGDRVT	ITCRASENIF	SYLAWYQQKP	GKSPKLLVYN	50'
TRTLAEGVPS	RFSGSGSGTD	FSLTISSLQP	EDFATYYCQH	HYGTPFTFGS	100'
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location

22-96	22''-96''	23'-88'	23'''-88'''	134'-194'	134'''-194'''	147-203	147''-203''
214'-223	214'''-223''	229-229''	232-232''	264-324	264''-324''	370-428	370''-428''

Modified lysines (ravtansine substituted)



Glycosylation sites (N)
300 & 300"

MOLECULAR FORMULA	$C_{6432}H_{9896}N_{1696}O_{2012}S_{42}$ $(C_{42}H_{58}ClN_3O_{11}S_2)_n$
MOLECULAR WEIGHT	148.12 kDa
TRADEMARK	None as yet
SPONSOR	Sanofi
CODE DESIGNATIONS	SAR408701
CAS REGISTRY NUMBER	2254086-60-5
UNII	DSS3BE2ZXN
WHO NUMBER	11356

gbk